DDX5 potentiates HIV-1 transcription as a co-factor of Tat. by Sithole, Nyaradzai et al.
Sithole et al. Retrovirology            (2020) 17:6  
https://doi.org/10.1186/s12977-020-00514-4
RESEARCH
DDX5 potentiates HIV-1 transcription 
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Abstract 
Background: HIV-1 does not encode a helicase and hijacks those of the cell for efficient replication. We and oth-
ers previously showed that the DEAD box helicase, DDX5, is an essential HIV dependency factor. DDX5 was recently 
shown to be associated with the 7SK snRNP. Cellular positive transcription elongation factor b (P-TEFb) is bound in 
an inactive form with HEXIM1/2 on 7SK snRNP. The Tat/P-TEFb complex is essential for efficient processivity of Pol II in 
HIV-1 transcription elongation and Tat competes with HEXIM1/2 for P-TEFb. We investigated the precise role of DDX5 
in HIV replication using siRNA mediated knockdown and rescue with DDX5 mutants which prevent protein–protein 
interactions and RNA and ATP binding.
Results: We demonstrate a critical role for DDX5 in the Tat/HEXIM1 interaction. DDX5 acts to potentiate Tat activ-
ity and can bind both Tat and HEXIM1 suggesting it may facilitate the dissociation of HEXIM1/2 from the 7SK-snRNP 
complex, enhancing Tat/P-TEFb availability. We show knockdown of DDX5 in a T cell line significantly reduces HIV-1 
infectivity and viral protein production. This activity is unique to DDX5 and cannot be substituted by its close paralog 
DDX17. Overexpression of DDX5 stimulates the Tat/LTR promoter but suppresses other cellular and viral promoters. 
Individual mutations of conserved ATP binding, RNA binding, helicase related or protein binding motifs within DDX5 
show that the N terminal RNA binding motifs, the Walker B and the glycine doublet motifs are essential for this func-
tion. The Walker A and RNA binding motifs situated on the transactivation domain are however dispensable.
Conclusion: DDX5 is an essential cellular factor for efficient HIV transcription elongation. It interacts with Tat and may 
potentiate the availability of P-TEFb through sequestering HEXIM1.
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Background
DEAD box RNA helicases are ubiquitous cellular pro-
teins with protean functions. They derive their name 
from the first letter amino acid sequence of their con-
served Walker B motif. They bind nucleic acids and are 
involved in many cellular processes including transcrip-
tion, pre-mRNA splicing, cellular differentiation, transla-
tion, RNA/protein stabilization and remodelling [1, 2].
Unlike a number of viruses that encode their own RNA 
helicases (such as the NS3 protein of Hepatitis C) [3, 4] 
Human immunodeficiency virus type 1 (HIV-1) does not, 
instead utilizing cellular helicases as essential cofactors at 
several stages of its replication cycle. The first of these to 
be identified was DDX3 which facilitates Rev mediated 
export of unspliced and partially spliced viral transcripts 
[5]. Subsequently DDX1 was shown to be a cofactor of 
Rev [6] while RNA helicase A (RHA) promotes HIV-1 
reverse transcriptase, transcription and translation 
[6–10].
We previously published a comprehensive siRNA 
knockdown screen of a library of 59 human cellular 
helicases. Amongst those identified as important HIV 
dependency factors were the two closely related DEAD 
box helicases, DDX5 and DDX17 [11]. Using siRNA 
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specific for knockdown of DDX5 and rescue with an 
siDDX5 resistant construct we have confirmed this phe-
notype in the physiologically relevant Jurkat cell line; 
knockdown having no detectable adverse effect on cellu-
lar viability.
DDX5 and DDX17 share 90% homology in their core 
regions and 60% and 30% similarity in their N and C ter-
mini respectively [12]. Because of their similarities and 
close interplay, they are sometimes considered as func-
tional homologs although each has been shown to have 
certain distinct roles [13–15]. The two proteins can exist 
as monomers, homodimers or heterodimers [16]. The 
complexity of their interaction is compounded by an as 
yet unexplained mechanism whereby overexpression of 
DDX5 results in a reduction in DDX17 [17]. We showed 
that DDX17 is a critical splicing factor for HIV-1 control-
ling the A4/5 splice acceptor site and that this function is 
independent of DDX5 [18].
Previous studies on DDX5 in the context of HIV-
1, have produced conflicting results. siRNA mediated 
knockdown was shown to increase HIV CA-p24 pro-
duction and infectivity, likely due to the documented 
increase in DDX17 expression noted in DDX5 depleted 
cells [19]. However in a different study in which DDX5 
was identified as a co-factor of Rev, knockdown appar-
ently reduced HIV-1 CA-p24 production and viral infec-
tivity [20]. Given these findings and the evidence we had 
suggesting that DDX5 is an HIV-1 dependency factor we 
sought to clarify the role of DDX5 in HIV-1 replication 
and whether its actions were dependent or independ-
ent of DDX17. Our evidence suggests that, despite their 
documented interplay in the cell, DDX5 and DDX17 have 
quite distinct and independent effects on HIV.
The integrated HIV-1 provirus is transcribed by cel-
lular RNA polymerase II (Pol II) and the mechanism of 
transcriptional initiation is similar to cellular genes. It 
differs in that the switch from initiation to elongation 
at the HIV-1 promoter is dependent on the viral trans-
activator Tat, which recruits P-TEFb to the stalled Pol II 
[21]. P-TEFb is composed of cyclinT1/2 (CycT1/2) and 
cyclin-dependent kinase 9 (Cdk9) [22–24]. The kinase 
catalytic domain phosphorylates the Ser2 residues in the 
C-terminal domain (CTD) of Pol II [24–26]. Formation 
of the Tat/P-TEFb complex is critical for efficient HIV-1 
transcription elongation [23]. In its absence Pol II termi-
nates prematurely soon after the TAR region due to poor 
processivity of the RNA Pol II/transcription complex [23, 
27, 28].
The majority of P-TEFb is sequestered, bound to 
HEXIM1 in the transcriptionally inactive 7SK snRNP 
complex, composed of 7SK snRNA, hexamethylene 
bisacetamide (HMBA) induced protein 1 (HEXIM1), 
methylphosphate capping enzyme (MEPCE) and Larp7/
Pip7S, in addition to P-TEFb [24, 26, 29–31]. Dynamic 
remodelling of 7SK snRNP regulates the availability of 
active P-TEFb [32]. A recent study has shown that KAP1 
recruits the 7SK snRNP complex to promoter proximal 
regions and, using mass spectrometry, interactors of 
LARP7 were identified, amongst which was DDX5 [33].
Tat competes with HEXIM1 to promote the release of 
P-TEFb increasing the available pool of active P-TEFb 
[30, 34]. The Tat binding region on 7SK snRNA is embed-
ded within the HEXIM1 binding domain and is struc-
turally and functionally indistinguishable from the Tat/
TAR binding region [35]. Tat forms two biochemically 
distinct complexes, Tatcom1 and Tatcom2. Formation 
of Tatcom2 which is devoid of HEXIM1 is thought to be 
either by Tat displacing HEXIM1 from 7SK snRNP by 
direct competition for 7SK RNA binding or by Tat being 
recruited to 7SK RNA during formation of 7SK snRNP 
[34]. Although it is not known how Tat eventually disso-
ciates from 7SK snRNA to enable it to bind P-TEFb, it is 
envisaged that Tat interacts dynamically with cellular fac-
tors that facilitate not only its binding with 7SK snRNA 
but also its release from the 7SK snRNA and subsequent 
presentation to the P-TEFb complex.
Here, we show that HIV-1 Tat can interact with DDX5 
and that, in the presence of DDX5, Tat has a competi-
tive advantage over HEXIM1 for recruitment of P-TEFb. 
We show that DDX5 interacts with HEXIM1. This could 
potentially sequester it as a mechanism of potentiating 
HIV-1 transcription elongation. Using mutational analy-
sis of individual motifs in the context of rescue experi-
ments, the domains of DDX5 essential for its role in 
HIV-1 replication have been identified. We also demon-
strate that DDX5 acts independently of DDX17.
Results
DDX5 is essential for HIV‑1 CA‑p24 production 
and infectivity
We used siDDX5A to knockdown, and siDDX5A resist-
ant expression constructs to rescue, expression of DDX5 
in HeLa cells. Cells were sequentially transfected with 
siDDX5A followed by a second round of siRNA together 
with the replication competent HIV-1 proviral clone 
pLAI, with or without increasing concentrations of an 
siDDX5A rescue plasmid. Knockdown and rescue of 
DDX5 were confirmed by western blotting (Fig.  1a). 
There was no detectable cellular toxicity following treat-
ment with siDDX5A with or without increasing concen-
trations of rescue plasmid (Additional file 1: Fig. S1a).
Supernatants from these transfected cells were used 
to infect the CD4+TZM-bl indicator cell line. DDX5 
knockdown reduced HIV-1 infectivity and both intra-
cellular and supernatant CA-p24 levels (Fig.  1b–d). 
All three parameters were successfully restored upon 
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Fig. 1 Effect of DDX5 knockdown and rescue on HIV-1 infectivity. a Western blot analysis of DDX5 knockdown and rescue. HIV-1 proviral clone 
pLAI, and siDDX5A with or without increasing concentrations of siDDX5A rescue expressor were transfected into HeLa cells. b HIV-1 infectivity 
following DDX5 knockdown and rescue. Cells were transfected with siDDX5A and then a second round of siRNA together with pLAI, with or without 
increasing concentrations of siDDX5A rescue construct. Supernatant was used to infect TZM-bl cells. Relative infectivity was calculated by dividing 
individual raw luminescence data with that from siControl treated cells. c Supernatant from b was harvested and CA-p24 quantified by ELISA. d Cell 
lysates from b were harvested and CA-p24 quantified by ELISA. Each graph is a representative of three independent experiments done in triplicate. 
e Linear regression of mean virion infectivity from triplicate samples on dose of DDX5A rescue plasmid are shown. f Per virion infectiousness was 
calculated using the virion infectivity (infectivity divided by supernatant CA-p24) and normalised to siControl treated cells. g Supernatant was 
harvested 48 h after co-transfection of a constant amount of pLAI with increasing concentrations of Myc-DDX5 and used to infect TZM-bl cells. The 
graph shown is representative of at least two independent experiments done in duplicate. Data is represented as mean of duplicate samples ± SEM. 
h Cell lysates from g were harvested and subjected to western blotting. i RT-qPCR analysis of unspliced, partially and fully spliced HIV-1 mRNA from 
left to right respectively. Cells were sequentially transfected with siControl or siDDX5A and then a second round of siRNA together with pLAI. Data 
shown is representative of three independent repeats, with triplicate samples for each siRNA. Data has been normalised to siControl. Error bars 
represent ± SEM. Values are scored as a fold-change relative to that of siControl treated cells. Statistical significance: *p < 0.05. See also Additional 
file 1: Figure S1
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co-expression of siDDX5A with the siDDX5A resistant 
DDX5 expressor, confirming that the observed pheno-
types were specifically due to DDX5 depletion.
Expression of the rescue plasmid not only restored 
viral infectivity, intracellular and supernatant CA-p24 
but could augment it above the level seen in siControl 
treated cells (Fig.  1b–d). We wondered whether this 
was due to a quantitative increase in virion production 
or if the virions produced had a higher specific infec-
tivity. The increased infection seen on rescue may have 
been unique to some characteristic of expression from 
the rescue plasmid or intrinsic to wild type DDX5. 
To address this, we performed a DDX5 overexpres-
sion experiment. HeLa cells were co-transfected with 
increasing amounts of DDX5 plasmid and a constant 
amount of pLAI. Virion infectivity was determined 
by dividing infectious virus release (determined using 
TZM-bl cells) by supernatant CA-p24 (quantified by 
ELISA) and expressed as a fraction of maximum. Lin-
ear regression of mean virion infectivity from triplicate 
samples on dose of DDX5A rescue plasmid are shown 
in Fig.  1e. Relative virion infectivity was measured by 
dividing the raw infectivity data for each condition 
with the infectivity data from siControl treated cells. 
The relative virion infectivity revealed that siDDX5 
treated cells have significant reduction in the infec-
tiousness of virions produced (Fig. 1f ). Overexpression 
of DDX5 resulted in a significant (fivefold) increase 
in HIV-1 infectivity (Fig. 1g, h). We postulate that the 
apparent increased infectivity per virion might be due 
to a number of causes including increased HIV tran-
scription or more efficient viral RNA modulation or 
stability. Knockdown of DDX5 resulted in a 3-fivefold 
reduction of each of the different HIV-1 mRNA spe-
cies (Fig.  1i) consistent with global inhibition of viral 
RNA production rather than differential effects on 
individual spliced forms.
Importance of DDX5 for HIV‑1 replication in a T cell line
To ensure that our findings were relevant to cell lines 
infectable by HIV-1, we carried out nucleofection of 
Jurkat cells using the HIV proviral clone pLAI together 
with siDDX5A with or without increasing concentra-
tions of the siDDX5A rescue plasmid. The same trend 
that we observed in HeLa cells was recapitulated. 
siRNA knockdown of DDX5 in Jurkat cells reduces 
HIV-1 infectivity and CA-p24 production; both char-
acteristics are rescued upon expression of the rescue 
plasmid (Fig. 2a, b). The siDDX5A rescue plasmid was 
well expressed in Jurkat cells (Fig. 2c).
DDX5 interacts with both Tat and HEXIM1 and facilitates 
efficient HIV‑1 transcription
DEAD box helicases typically influence either transcrip-
tional or post-transcriptional events [36] and there is 
published evidence that DDX5 can affect transcription of 
cellular genes [37, 38].
Previous in  vitro studies have revealed that Tat can 
interact with DDX5 [39]. However, to our knowledge 
there are no studies showing this in a cellular context. 
To seek evidence of interaction between DDX5 and Tat 
or the P-TEFb complex we performed co-immunopre-
cipitations. Myc tagged DDX5 was co-transfected with 
HIV-1 replication competent proviral plasmid in HeLa 
cells. Due to the fact that there is little de-novo synthe-
sis of Tat we used transfected whole cell lysates as posi-
tive control. HIV Tat co-immunoprecipitates with DDX5 
(Fig. 3a), but not the P-TEFb components Cyclin T1 and 
CDK9 (Additional file 2: Fig. S2a, b). Given that HEXIM1 
competes with Tat for P-TEFb at the 7SK snRNP, we 
wondered if DDX5 could interact with HEXIM1. We 
found that DDX5 co-immunoprecipitates with HEXIM1 
(Fig.  3b). To seek any potentiating effect of DDX5 on 
Tat, we transfected siDDX5 together with a Tat expres-
sor in TZM-bl indicator cells. Knockdown of DDX5 
significantly reduced the Tat driven luciferase activity 
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Fig. 2 DDX5 is essential for HIV-1 infectivity and CA-p24 production 
in Jurkat cells. a HIV-1 infectivity following DDX5 knockdown 
and rescue in Jurkat cells. Supernatant was harvested 96 h post 
nucleofection and used to infect TZM-bl cells. b Cell lysates were 
harvested 96 h post nucleofection and CA-p24 quantified by ELISA. 
Bars represent mean of duplicate samples ± SEM. c Western blot 
showing the expression of DDX5 following knockdown and rescue
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(Fig. 3c). To further establish that DDX5 potentiates Tat, 
we performed a DDX5 dose dependence experiment by 
co-transfecting a constant concentration of Tat expres-
sor with increasing concentrations of DDX5 in TZM-bl 
cells. Overexpression of DDX5 resulted in a significant 
increase in the Tat driven luciferase activity (Fig. 3d, e). 
Further experiments to confirm that DDX5 potentiates 
Tat driven LTR activity were carried out by co-transfec-
tion of increasing concentration of DDX5 with constant 
amount of Tat expressor and LTR- driven luciferase 
reporter construct in Hela cells (Additional file  3: Fig. 
S3a, b). Overexpression of DDX5 significantly increased 
Tat driven luciferase activity and knockdown of DDX5 
reduced Tat driven luciferase activity (Additional file  3: 
Fig. S3a, c).
DDX5 thus can interact with Tat and HEXIM1 and 
enhances Tat dependent transcription. To determine 
whether DDX5 potentiation of Tat is HIV-1 LTR pro-
moter specific and not due to non-specific transcriptional 
enhancing effects of DDX5, we transfected in independ-
ent experiments, three different luciferase reporter con-
structs under different promoters. Overexpression of 
DDX5 assessed by Western blot (Additional file  3: Fig. 
S3g, h and i) has a significant dominant negative effect on 
human elongation factor driven luciferase activity (Addi-
tional file  3: Fig. S3d), CMV driven luciferase activity 
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Fig. 3 DDX5 is specifically required for HIV-1 transcription and interacts with HIV Tat and cellular HEXIM1. a Myc-DDX5 was co-transfected with 
HIV-1 replication competent proviral construct (pLAI). Cells were harvested after 48 h and subjected to co-immunoprecipitation followed by 
western blot for HIV Tat. DDX5 co-immunoprecipitates with Tat. Hela whole cell lysates from cells transfected with replication competent HIV-1 
proviral plasmid, were run in parallel as positive control for HIV Tat, to the immunoprecipitation treated samples. The blot is a representative of three 
independent experiments. b Myc-DDX5 was co-transfected with HIV-1 proviral construct (pLAI). Cells were harvested after 48 h and subjected to 
co-immunoprecipitation followed by western blot for HEXIM1. Representative western blot of three independent experiments showing that DDX5 
co-immunoprecipitates with HEXIM1. c TZM-bl cells were transfected with constant amount of Tat expressor plus either siControl or siDDX5A. Cell 
lysates were harvested after 72 h and luciferase activity measured using the luciferase assay. The graph is a representative of three independent 
experiments done in triplicate. Bars represent mean of triplicate samples ± SEM. d DDX5 potentiates Tat dependent, HIV-1 LTR-driven, firefly 
luciferase activity. TZM-bl cells were co-transfected with pcDNA3.0-Tat and increasing concentration of Myc-DDX5. Cells were harvested after 48 h 
and luciferase activity measured. The graph shown is a representative of three independent experiments done in duplicate ± SEM. e Western blot 
showing the expression levels of DDX5 in TZM-bl cells. Statistical significance: *P < 0.05. See also Additional file 2: Figure S2 and Additional file 3: 
Figure S3
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(Additional file 3: Fig. S3e) and T7 promoter driven lucif-
erase activity (Additional file 3: Fig. S3f ).
The role of DDX5 in HIV‑1 is independent of its paralog 
DDX17
Given the intimate relationship between DDX5 and 
DDX17 we next queried whether the transcriptional 
enhancement of DDX5 on HIV-1 was dependent or inde-
pendent of its paralog. We transfected either Myc tagged 
DDX17 or a Myc tagged DDX5 expressor in HeLa cells. 
Cells were harvested, and nuclear extracts prepared fol-
lowed by either pulldown of Myc-DDX17 or Myc-DDX5 
and immunoblotting for DDX5 or DDX17 respectively. 
We could confirm by co-immunoprecipitation the pub-
lished findings that DDX5 interacts with DDX17 (Addi-
tional file  4: Fig. S4a, b). Myc-DDX17 or Myc-DDX5 
was transfected in HeLa cells and cell lysates harvested 
after 48 h for co-immunoprecipitation. Additional file 4: 
Figure S4a shows pulldown of Myc-DDX17 followed by 
immunoblotting for DDX5. Additional file 4: Figure S4b 
shows pulldown of Myc-DDX5 followed by immunoblot-
ting for DDX17. siRNA knockdown of DDX5 up-regu-
lates levels of DDX17 although this is non reciprocal [19, 
40]. Overexpression of DDX5 downregulates endogenous 
DDX17 (Additional file 4: Fig. S4c) [17]. Our findings that 
overexpression of DDX5 reduces DDX17 expression yet 
leads to an increase in HIV-1 replication supports the 
case that DDX5 has a direct role in HIV-1 independent 
of DDX17. To further distinguish the roles of these two 
proteins, we attempted to rescue DDX5 knockdown by 
overexpression of DDX17 however this failed to restore 
HIV-1 infectivity (Fig. 4a, b). These findings underscore 
that DDX5 is a critical factor for HIV-1 replication inde-
pendent of DDX17.
DDX5 utilises distinct RNA binding motifs to facilitate 
efficient HIV‑1 replication
We investigated whether the transcriptional activity of 
DDX5 in HIV-1 replication was dependent on its nucleic 
acid binding or modifying functions. We introduced indi-
vidual point mutations in known RNA and ATPase bind-
ing motifs and cloned each mutant into the siDDX5A 
rescue backbone. We tested individual mutant constructs 
in the context of HIV-1 replication by measuring their 
ability to restore viral infectivity and CA-p24 production 
in DDX5 depleted cells.
The Q motif is necessary for binding of ssRNA and, 
through its interaction with motif 1a, it is important 
for ATP binding, acting as a regulator of ATPase activ-
ity. Substituting the highly conserved glutamine residue 
(aa121) by alanine abrogates ATP/RNA binding [41, 42]. 
The siDDX5A resistant DDX5-Q121A construct failed to 
restore production of infectious virus (Fig. 5a, b).
Motif 1a (PTRELA) and 1b (TPGR) are necessary for 
RNA binding in conjunction with motifs IV and V [43]. 
Introducing individual point mutations within either 
motif 1a (PTRELA to PRRVAA) or motif 1b (TPGR to 
DPGR) abrogates ATP/helicase and RNA binding activi-
ties respectively [44]. Furthermore, the mutant TPGR 
to DPGR has a detrimental effect on ATPase, RNA 
crosslinking and helicase activities [44]. In the context of 
rescue experiments, both mutants fail to restore HIV-1 
infectivity (Fig. 5c, d). All three mutants, DDX5-Q121A, 
DDX5-T176R+E178V+L179A and DDX5-T224D failed 
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Fig. 4 DDX5 acts independently of DDX17. a Cells were sequentially transfected with siDDX5A and then a second round of siRNA together with 
pLAI, with or without increasing concentrations of a DDX17 expressor. Supernatant was harvested after 48 h and used to infect TZM-bl cells. 
The graph shown is a representative of three independent experiments done in triplicate. Bars represent mean of triplicate samples ± SEM. b 
Knockdown and rescue was determined by western blotting for DDX5 and DDX17 expression. Statistical significance: **P < 0.01. See also Figure S4
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to restore CA-p24 production, despite adequate expres-
sion (Fig. 5e–j).
Thus, individually abrogating the Q motif or motifs 
1a and 1b in the rescue construct failed to restore viral 
infectivity supporting the notion that they are critical 
components of DDX5 function in the HIV replication 
cycle.
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Fig. 5 DDX5 N terminal RNA binding motifs are indispensable in HIV-1 replication. a Schematic representation of DDX5 and the annotated 
individual point mutations that are defective for ATPase and RNA binding activities in the Q motif and motifs 1a and 1b. b HIV-1 infectivity 
following DDX5 depletion and rescue with siDDX5A-resistant, Q motif mutated plasmid DDX5-Q121A. Supernatant from transfected cells 
was used to infect TZM-bl cells. c HIV-1 infectivity following DDX5 depletion and rescue with siDDX5A-resistant, motif 1a mutated plasmid, 
DDX5-T176R + E178V + L179A. Supernatant from transfected cells was used to infect TZM-bl cells. d HIV-1 infectivity following DDX5 depletion and 
rescue with siDDX5A-resistant, motif mutated plasmid, DDX5-T224D. Supernatant from cells transfected with siDDX5A and then a second round of 
siRNA together with pLAI, with or without increasing concentrations of DDX5-T224D construct, was used to infect TZM-bl cells. e Cell lysates from 
b were harvested and CA-p24 quantified by ELISA. f Cell lysates from c were harvested and CA-p24 quantified by ELISA. g Cell lysates from d were 
harvested and CA-p24 quantified by ELISA. Each graph is a representative of at least two independent experiments done in triplicate. Bars represent 
mean of triplicate samples ± SEM. h Western blot showing the expression of DDX5 after knockdown and rescue with DDX5-Q121A. i Western blot 
showing the expression of DDX5 after knockdown and rescue with DDX5-T176R + E178V + L179A. j Western blot showing the expression of DDX5 
after knockdown and rescue with DDX5-T224D. Statistical significance *P < 0.05, **P < 0.01. See also Additional file 4: Figure S4
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Surprisingly expression of the RNA binding defective 
mutants DDX5-S279L and DDX5-R431Q, situated within 
the transactivation domain of DDX5, restored HIV-1 
infectivity (Additional file  5: Fig. S5a–e). Thus, unlike 
those at the N terminus, the RNA binding motifs within 
the transactivation domain are not important for HIV 
transactivation. Attempts to truncate the transactiva-
tion domain and use the resulting mutant in RNAi rescue 
experiments were not successful as the mutant could not 
be expressed at comparable levels to the wild type.
DDX5 DEAD box signature motif (Walker B) is essential 
for HIV‑1 replication
We introduced siRNA-resistant DDX5 constructs with 
either abrogated Walker A or Walker B activity to DDX5 
depleted cells (Fig. 6a). Mutating the conserved lysine to 
alanine residue in Walker A abolishes its ATPase activ-
ity by reducing the affinity for and the rate of hydrolysis 
of ATP [45]. However, the Walker A motif which is cru-
cial in ATPase and helicase activities is dispensable for 
the role of DDX5 in HIV-1 replication since a siDDX5A 
rescue mutant with abrogated Walker A (DDX5-K144A) 
activity successfully restores viral infectivity (Fig.  6b). 
Expression levels of the mutant did not vary significantly 
(Fig. 6c).
The Walker B motif (DEAD) is well characterised for 
its role in helicase activity [1]. A point mutation (DEAD 
to DQAD) that abolishes helicase activity (siDDX5A 
resistant DDX5-E249Q) (Fig.  6a), failed to restore viral 
infectivity and CA-p24 production despite adequate 
expression (Fig. 6d–f), indicating the helicase activity of 
the Walker B motif is essential for HIV-1 replication.
Disruption of the DDX5 protein/protein interaction domain 
inhibits HIV‑1 replication
DEAD box helicases share a highly conserved glycine 
doublet, thought to facilitate the formation of a sharp 
turn within the loop between motif 1a and motif 1b. It 
is essential for protein–protein interactions with other 
proteins [1] and vital for the latter motifs to retain RNA 
binding activity. Substituting the second glycine residue 
with aspartic acid disrupts the formation of the turn. 
This mutant has also been shown to lack ATPase and 
RNA helicase activity but retains ATP binding activity 
[44]. We generated DDX5-G203D (Fig. 7a) to interrogate 
the glycine doublet. Despite DDX5-G203D being well 
expressed, following depletion of endogenous DDX5, it 
failed to restore viral infectivity and CA-p24 production 
(Fig. 7b–d).
The glycine doublet is critical for DDX5 to facilitate its 
role in HIV-1 transcription. However, our experimental 
design does not differentiate whether failure of DDX5-
G203D mutant to restore viral infectivity and CA-p24 
production is a result of disruption of its protein–protein 
interaction activity or RNA binding.
DDX5 interaction with HEXIM1 is mediated via RNA 
binding and Walker B motif
Given that DDX5 utilises distinct RNA binding motifs 
and the highly characterised Walker B motif is essen-
tial for DDX5′s role in potentiating HIV transcription, 
we performed co-immunoprecipitation experiments 
to determine whether the loss of function of DDX5-
T176R + E178V + L179A and DDX5-E249Q was due 
to loss of interaction with HEXIM1. The respective 
Myc tagged constructs of DDX5 wild type (wt), DDX5-
T176R + E178V + L179A and DDX5-E249Q were co-
transfected with HIV-1 proviral plasmid (pLAI) in HeLa 
cells. We found that both DDX5-T176R + E178V + L179A 
and DDX5-E249Q lose the ability to co-immunoprecip-
itate with HEXIM1. This would be consistent with the 
interaction of DDX5 and HEXIM1 being RNA dependent 
(Fig. 8a). The different Myc tagged DDX5 constructs were 
well expressed as assessed by western blot (Fig. 8b).
Discussion
HIV-1 transcription is a multistep process that is regu-
lated and coordinated to promote efficient viral replica-
tion. Efficient Pol II processivity beyond the TAR region 
requires the presence of the Tat/P-TEFb complex [23, 
46]. Tat/P-TEFb complex formation involves a series of 
dynamic transient interactions with different cellular fac-
tors, including snRNA. and sequential rearrangement of 
intermediate complexes.
Cellular P-TEFb is stored mainly in the inactive form 
sequestered with HEXIM1/2 bound to the 7SK snRNP 
complex, HIV-1 Tat competes with HEXIM1/2 to disrupt 
its binding on P-TEFb [23] however detailed understand-
ing of the molecular mechanisms behind Tat dislodging 
HEXIM1/2 and then successfully preventing HEXIM1/2 
from binding to free P-TEFb has been lacking. We show 
that DDX5 knockdown reduces HIV expression and 
that this can be rescued with exogenous DDX5. Over-
expression of DDX5 significantly increases expression 
of HIV indicating that DDX5 is a powerful cofactor for 
Tat. Our co-immunoprecipitation data reveal that DDX5 
can interact with both Tat and HEXIM1 within the cell 
and that it has a significant potentiating effect when co-
expressed with a Tat expressing plasmid in TZM-bl cells 
(Fig.  3a–e) and in Hela cells (Additional file  3: Fig. S3a, 
b) providing a plausible scenario that DDX5/Tat interacts 
with the 7SK snRNP releasing P-TEFb and sequestering 
HEXIM to block its inhibitory effect. Consistent with 
this we could not detect DDX5 interacting with other 
P-TEFb components (Cyclin T1 or CDK9) (Additional 
file 2: Fig. S2a, b). We thus describe a novel component 
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Fig. 6 DDX5 Walker A is dispensable but Walker B (DEAD) helicase activity is required. a Schematic representation of DDX5 and the annotated 
individual point mutations in the Walker A and Walker B (DEAD) motifs that are defective for ATPase and helicase activity respectively. b HIV-1 
infectivity following DDX5 depletion and rescue with siDDX5A-resistant, Walker A motif mutated plasmid, DDX5-K144A. Supernatant from 
transfected cells was used to infect TZM-bl cells. c Western blot showing the expression of DDX5 after knockdown and rescue with DDX5-K144A. 
d HIV-1 infectivity following DDX5 depletion and rescue with siDDX5A-resistant, Walker B motif mutated plasmid, DDX5-E249Q. Supernatant from 
transfected cells was used to infect TZM-bl cells. e Cell lysates from d were harvested and CA-p24 quantified by ELISA. Each graph is a representative 
of at least two independent experiments done in triplicate. Bars represent mean of triplicate samples ± SEM. Statistical significance *P < 0.05, 
**P < 0.01, ***P < 0.0001. f Western blot showing the expression of DDX5 after knockdown and rescue with DDX5-E249Q
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of this regulatory machine, DDX5, and add an additional 
layer to transcriptional control of HIV and show that 
this is specific for the Tat/LTR system and not a general 
enhancing effect on transcription by DDX5. Evidence of 
molecular mimicry between viral and host-protein-RNA 
complexes (Tat-TAR and HEXIM1-7SK snRNA) has been 
used to suggest that Tat competitively displaces HEXIM1 
from 7SK snRNA [9]. The fact that DDX5 was recently 
identified by mass spectrometry as one of the LARP7 
interactors reinforces our findings that DDX5 can inter-
act with components of the 7SK snRNP complex and 
strengthens our evidence that it is critical for efficient 
HIV-1 replication.
DDX5 can exist as a monomer and a homodimer or can 
form heterodimers with its paralog DDX17. The two heli-
cases have many functions in common. Based on the sub-
stitution findings (Fig. 4a, b) we conclude that the effects 
of DDX5 on HIV replication are independent of DDX17. 
Thus, an increase in DDX17 seen upon DDX5 depletion 
is not responsible for the phenotype produced by manip-
ulating DDX5.
We delineated the DDX5 motifs and the biochemical 
activities that are essential for its role in HIV-1 replica-
tion. DDX5 utilises distinct RNA binding and ATPase 
motifs, namely: Q, 1a and 1b motifs (Fig.  5a–j) and the 
glycine doublet motif (Fig. 7a–d). The Walker A ATPase 
activity and the RNA binding activities of DDX5-S279L 
and DDX5-R431Q were dispensable for DDX5 medi-
ated transactivation. Although the ATPase activity of the 
Walker A motif is dispensable, rather surprising is the 
requirement for the ATPase activity of the Q motif. The 
Q motif ’s ability to efficiently bind ssRNA rather than 
its ATPase activity might be required [1, 41]. Therefore, 
although RNA and ATPase activities are essential these 
functions are mediated through specific RNA and ATP 
binding motifs by DDX5.
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Fig. 7 DDX5 glycine doublet is essential for efficient HIV-1 replication. a Schematic representation of DDX5 and the annotated individual point 
mutations in the glycine doublet motif that is defective for ATPase/helicase activities and protein–protein interactions. b HIV-1 infectivity following 
DDX5 depletion and rescue with siDDX5A-resistant, glycine doublet motif mutated plasmid, DDX5-G203D. Supernatant from transfected cells 
was used to infect TZM-bl cells. c Cell lysates from b were harvested and CA-p24 quantified by ELISA. Each graph is a representative of at least two 
independent experiments done in triplicate. Bars represent mean of triplicate samples ± SEM. Statistical significance **P < 0.01. d Western blot 
showing the expression of DDX5 after knockdown and rescue with DDX5-G203D
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The Walker B (DEAD) motif (helicase motif ) is indis-
pensable yet, strikingly, the helicase activity of motif III 
is dispensable (Additional file 4: Fig. S4a, b). Mutations in 
motif III have been shown to cause minor effects on ATP 
binding, hydrolysis and RNA binding but cause a signifi-
cant loss of helicase activity [47, 48].
Motif VI (HRIGRTGR), at the interface between 
domains 1 and domain 2, is important for ATPase activ-
ity and RNA binding. Mutating the arginine residue to 
glutamine abrogates both its ATPase and RNA bind-
ing activity [44, 48, 49] however the siDDX5A resist-
ant-DDX5-R431Q mutant successfully restored HIV-1 
infectivity indicating it is dispensable for HIV-1 replica-
tion (Additional file 5: Fig. S5a, c). Both DDX5-S279L and 
DDX5-R431Q in the siDDX5A rescue plasmid are suc-
cessfully expressed (Additional file 5: Fig. S5d, e).
RNA binding motifs III and VI are independent 
of each other and independent of the RNA bind-
ing motifs 1a and 1b [1]. Therefore, our findings that 
both siDDX5A resistant mutants DDX5-S279L and 
DDX5-R431Q successfully restored HIV-1 infectivity 
suggest that neither motif III nor motif VI is required 
for DDX5 to affect HIV-1 replication. However, RNA 
binding motifs 1a and 1b are essential [1] and mutat-
ing one or the other resulted in failure to restore viral 
infectivity. This point towards DDX5′s role in HIV-1 
transcription probably being independent of its trans-
activation domain (TAD) as both DDX5-S279L and 
DDX5-R431Q which are situated within the TAD are 
dispensable.
Identification of these functional motifs will be inval-
uable in further mapping and understanding the critical 
cofactors involved in the effect of DDX5 in facilitating 
and enhancing HIV expression. We have shown that 
RNA is required for interaction of DDX5 with HEXIM1 
but whether this is cellular or viral RNA is as yet 
unclear. The mechanistic model we propose is consist-
ent with DDX5 interacting with HIV-1 Tat and seques-
tering HEXIM1 thereby facilitating P-TEFb access to 
Tat to permit efficient HIV-1 transcription processivity 
(Fig. 8c).
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Fig. 8 DDX5 RNA binding motif 1a and the Walker B motif are essential for interaction with HEXIM1. a HeLa cells were co-transfected with 
different Myc-tagged DDX5 expressors (DDX5 wild type, DDX5-T176R + E178V + L179A and DDX5-E249Q). Cell lysates were harvested 48 h post 
co-transfection for co-immunoprecipitation. A Myc specific antibody or isotype matched control antibody was used for pull-down. Samples 
were subjected to SDS-PAGE and western blotting by probing for HEXIM1. To further validate that the interaction of DDX5 with HEXIM1 is 
RNA dependent, samples from Myc-DDX5 wild type were treated with RNase enzyme. The western blot shown is a representative from three 
independent experiments. b Western blot from whole cell lysates transfected with the different Myc-DDX5 constructs to ascertain level of 
expression. HeLa cells were co-transfected with different Myc-tagged DDX5 expressors (DDX5 wild type, DDX5-T176R + E178V + L179A and 
DDX5-E249Q). Cell lysates were harvested 48 h post transfection for Western blot using a Myc specific antibody. Mock or untransfected cell lysates 
were used as control. c Graphical abstract showing the proposed mechanistic action of DDX5 in HIV-1 transcription processivity
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Conclusions
The DEAD box helicase DDX5 interacts with Tat/
HEXIM1 and is necessary for HIV transcription. There is 
clear evidence that the role of DDX5 in HIV replication 
is independent of its paralog, DDX17. We show that the 
DDX5 motifs; Q, 1a, 1b, glycine doublet and Walker B are 
essential for DDX5′s role in HIV replication. The specific 
function of DDX5 to interact with HEXIM1 is essential 
for HIV-1 replication and may have more widespread 
implications in cell biology.
Methods
Cells and plasmids
HeLa M, a derivative of HeLa cells [50] were obtained 
from ATCC. TZM-bl cells, carrying two HIV-1 LTR-
driven reporter genes, firefly luciferase and E. coli 
β-galactosidase [51, 52], is a HeLa cell clone that stably 
expresses high levels of CD4, CXCR4 and CCR5 recep-
tors, was obtained from NIH AIDS Research and Refer-
ence Reagent Program. HeLa M and TZM-bl cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS). Jurkat 
cells (obtained from NIBSC Centre for AIDS Research 
London, UK) were grown in RPMI supplemented with 
10% FBS. Generation of the siDDX5A resistant con-
structs was performed using the site directed mutagen-
esis (SDM) kit (Agilent). See Additional file  6: Table  S1 
for primer sequences. Myc tagged DDX5 and DDX17 
were kind gifts from Dr Frances Fuller-Pace (Dundee). 
An empty cloning vector pBluescript (Stratagene) was 
used to maintain a constant amount of DNA in transfec-
tion experiments. pLAI is a full-length molecular clone 
of HIV-1 strain LAI for the expression of wild type virus 
[53]. pcDNA3.0-Tat is a Tat expressor under the CMV 
promoter (a kind gift of Dr J Sodroski, Harvard).
Cell viability
CellTiter-Glo Luminescent Cell Viability Assay (Pro-
mega) was adapted for 96-well half-area plates and assay 
performed as previously described [54].
siRNA and plasmid DNA transfections
siDDX3, siDDX5A, siDDX17 and siControl were pur-
chased from Life Technologies. See Additional file  7: 
Table  S2 for siRNA sequences. Sequential transfections 
were performed at 24  h (1  µl of 20  µM siRNA alone) 
and 48  h (siRNA + DNA plasmids) post seeding in 24 
well plates. A constant amount, 200  ng of pLAI was 
used. In the rescue experiments, in addition to siDDX5A 
and pLAI, HeLa cells were co-transfected with increas-
ing amounts of various siDDX5A resistant constructs. 
All transfections were carried out using jetPRIME 
(Polyplus) transfection reagent per the manufacturer’s 
protocol. Cells and supernatant were harvested 48  h 
post co-transfection and the supernatant was used to 
infect CD4 + TZM-bl cells to assay for viral infectivity. 
To assess siRNA mediated knockdown and rescue cell 
lysates were subjected to western blotting.
Nucleofection
Amaxa®  Nucleofector® II Device and  Amaxa® cell line 
 Nucleofector® Kit V (Cat. No. VCA 1003) from Lonza 
was used for nucleofection of Jurkat cells per the manu-
facturer’s protocol. Cells were sub-cultured in 12 well 
plates for 48  h and  1x106 cells per condition were used 
for nucleofection with 2  µg DNA plasmid of either test 
sample or control plasmid  (pmaxGFP®Vector) together 
with 30  pmol/sample siRNA (either siControl or siD-
DX5A). 48  h post nucleofection, medium was replaced 
with fresh RPMI 1640. Cell culture supernatant and cell 
lysates were harvested 96 h post nucleofection.
Virus infectivity assay
Virus infectivity in culture supernatants was deter-
mined by infecting TZM-bl indicator cells, based on 
Tat-dependent upregulation of LTR-driven luciferase 
expression. Cell lysates were harvested 48  h post infec-
tion. 5 µl of cell lysate were transferred to a 96-well half-
area plate, to which 25 µl of Luciferase Assay Reagent was 
added. Firefly luciferase activity was quantified using the 
Luciferase Assay System with the Glomax 96 Microplate 
Luminometer (Promega).
Nuclear extracts preparation and co‑immunoprecipitation
HeLa cells were co-transfected with the appropriate 
Myc-tagged constructs and pLAI. Cells were harvested 
48  h post transfection and nuclear extracts prepared as 
previously described [55, 56] with the following buffers 
and modifications: Lysis buffer containing 10 mM HEPES 
pH 7.9; 1.5 mM  MgCl2; 10 mM KCl; 0.5 mM DTT sup-
plemented with protease inhibitors (Roche). This was 
followed by 5 µl per 500 µl reaction mix RNase (Sigma) 
treatment for 10  min at 4  °C. Samples were incubated 
overnight with 2 µg of either Myc or Isotype control anti-
body in CO-IP buffer (20 mM HEPES (pH 7.9); 150 mM 
NaCl; 0.5 mM DTT; 20% (v/v) Glycerol; 10 mM NaF and 
protease inhibitors). Samples were then incubated with 
A/G ultralink Sepharose beads (Thermoscientific) for 3 h 
at 4  °C. After washing with CO-IP buffer, samples were 
eluted in 2X Laemmli sample buffer. Proteins were sepa-
rated by SDS-PAGE followed by western blotting using 
standard protocol.
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Western blotting
Proteins were separated by SDS-PAGE before being 
subjected to western blot. The following antibod-
ies were from Santa Cruz: Myc (9E10), DDX17 
(sc-398168), Abcam: HIV-Tat (ab43014), HEXIM1 
(ab25388), Cyclin T1 (ab176702), CDK9 (ab6544), Rab-
bit Isotype matched control IgG (ab27478), Rabbit 
c-Myc (ab39688) and GAPDH (ab9485). DDX5 anti-
body PAb-204 was a kind gift from Dr Frances Fuller-
Pace (Dundee). HIV-1 p55/p24 (ARP, NIBSC) [57]. 
Mouse IgG Isotype control (401402) was obtained from 
Biolegend. The following secondary antibodies were 
from: Cell Signalling: horseradish peroxidase (HRP)-
conjugated anti-mouse (#7076, 1: 2000), Santa Cruz: 
HRP-conjugated anti-rabbit (#2123, 1: 2000). Detection 
was carried out using ECL prime (Amersham) per the 
manufacturer’s instructions.
Enzyme‑linked immunosorbent assay
Extracellular and intracellular/supernatant CA-p24 lev-
els were quantified by ELISA (Alto) with slight modifi-
cation [58].
RT‑qPCR
HeLa cells were sequentially transfected with siRNA 
and DNA plasmids as previously described in 24 well 
plates. Total RNA was extracted using RNeasy kit 
(Qiagen) per the manufacturer’s instructions. 5  µg of 
total RNA was used for complementary DNA synthe-
sis with random hexamers, using reverse-transcription 
kit (Applied Biosystems). Applied Biosystems 7500 HT 
Fast Real Time PCR System (Life Technologies) and 
SYBR green qPCR reagent (Applied Biosystems) were 
used for qPCR. Primer sequences and thermo-cycling 
conditions have been previously described [59, 60] and 
are shown in Additional file 6: Table S1 and Additional 
file  8: Table  S3 respectively. The specificity of qPCR 
products was examined by a dissociation curve and rel-
ative abundance of transcripts was calculated using the 
 2−∆∆CT method [61]. Results were normalised to Actin 
and mean results of triplicates were converted to ratios 
relative to siControl samples.
Statistical analyses
Statistical analyses were performed in Excel and Graph-
Pad Prism version 4. The data for viral infectivity and 
CA-p24 production were analysed by unpaired two-
tailed Student’s t test, with Welch’s correction.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1297 7-020-00514 -4.
Additional file 1. Figure S1. Cell viability. (A and B) Cells were seeded in a 
96 well at 4 × 103 cells per well and sequentially transfected with 10 pmol 
of siControl or siDDX5A and then a second round of siRNA together with 
or without increasing concentrations of siDDX5A rescue constructs. The 
number of viable cells was determined by measuring the amount of ATP 
present as an indicator of metabolically active cells. This was then calcu-
lated as a percentage relative to untransfected cells. Puromycin treated 
cells were used as positive controls. Bars represent mean of duplicate 
samples ± SEM.
Additional file 2: Figure S2. DDX5 does not co-immunoprecipitate with 
P-TEFb (Cyclin T1 and CDK9). (A and B) HeLa cells were co-transfected with 
Myc-DDX5 and pLAI. Cell lysates were harvested 48 h post co-transfection 
for co-immunoprecipitation. A Myc specific antibody or isotype matched 
control antibody (IgG) was used for pull-down. Samples were then 
subjected to SDS-PAGE and western blotting by probing for Cyclin T1 and 
CDK9 respectively. Positive control for Myc-DDX5 pulldown was confirmed 
by the pulldown of Myc-DDX5 and immunoblotting for DDX17 (Fig. S4) as 
the two are known to form heterodimers in cells.
Additional file 3: Figure S3. DDX5 specifically potentiates Tat driven 
LTR luciferase activity. (A) HeLa cells were co-transfected with constant 
amount of 3′LTR-Luciferase and Tat expressors plus increasing concentra-
tion of DDX5. Cell lysates were harvested 48 h and luciferase activity meas-
ured using the luciferase assay. The graph is a representative of three inde-
pendent experiments done in triplicate. Bars represent mean of triplicate 
samples ± SEM. (B) Western blot showing the overexpression of DDX5. (C) 
Hela cells were transfected with constant amount of 3′LTR-Luciferase and 
Tat expressors plus either siControl or siDDX5A. Cell lysates were harvested 
after 72 h and luciferase activity measured using the luciferase assay. 
The graph is a representative of three independent experiments done 
in triplicate. Bars represent mean of triplicate samples ± SEM. Statistical 
significance *P < 0.05. (D) Hela cells were co-transfected with a constant 
amount of pEF-Luciferase plus increasing concentration of DDX5 expres-
sor. Cell lysates were harvested after 72 h and luciferase activity measured 
using the luciferase assay. (E) Hela cells were co-transfected with a 
constant amount of pcDNA3.1-Luciferase plus increasing concentration of 
DDX5 expressor. Cell lysates were harvested after 72 h and luciferase activ-
ity measured using the luciferase assay. (F) Hela cells were co-transfected 
with a constant amount of pJL-Luciferase plus increasing concentration 
of DDX5 expressor. Cell lysates were harvested after 72 h and luciferase 
activity measured using the luciferase assay. (G) Western blot showing the 
overexpression of DDX5 and GAPDH as loading control in cell lysates from 
(D). (H) Western blot showing the overexpression of DDX5 and GAPDH 
as loading control in cell lysates from (E). (I) Western blot showing the 
overexpression of DDX5 and GAPDH as loading control in cell lysates from 
(F). The graphs, (D, E and F) are from two independent experiments done 
in triplicates for each different luciferase expressor. Bars represent mean of 
triplicate samples ± SEM. Statistical significance ****P < 0.0001.
Additional file 4: Figure S4. DDX5 interacts with DDX17 and effects of 
DDX5 overexpression on endogenous DDX17 levels. (A) HeLa cells were 
co-transfected with Myc-DDX17. Cell lysates were harvested 48 h post 
co-transfection for co-immunoprecipitation. A Myc specific antibody or 
isotype matched control antibody (IgG) was used for pull-down. Samples 
were subjected to SDS-PAGE and western blotting by probing for DDX5. 
(B) HeLa cells were co-transfected with Myc-DDX5. Cell lysates were 
harvested 48 h post co-transfection for co-immunoprecipitation. A Myc 
specific antibody or isotype matched control antibody (IgG) was used for 
pull-down. Samples were subjected to SDS-PAGE and western blotting 
by probing for DDX17. (C) Effect of overexpressing DDX5 wild type on the 
expression level of endogenous DDX17. HeLa cells were co-transfected 
with a constant amount of pLAI and increasing concentrations of DDX5 
wild type expressor construct. Cell lysates were harvested 48 h post co-
transfection followed by western blotting for DDX5 and DDX17.
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Additional file 5: Figure S5. DDX5 ATPase and RNA binding motifs 
mutants are essential for Tat activity. (A) Schematic representation of DDX5 
and the annotated individual point mutations that render DDX5 defective 
for RNA binding activities in motifs III and IV. (B) Effect on HIV-1 infectivity 
following endogenous DDX5 depletion and rescue with DDX5-S279L. 
Cells were sequentially transfected with siDDX5A and then a second 
round of siRNA together with the replication competent HIV-1 proviral 
clone pLAI, with or without increasing concentrations of siDDX5A resistant 
DDX5-S279L expressor construct. Supernatant was harvested 48 h post 
co-transfection and used to infect CD4 + TZM-bl indicator cells for assess-
ing viral infectivity. TZM-bl cell lysates were harvested 48 h post infection 
and luciferase activity quantified. (C) Effect on HIV-1 infectivity following 
endogenous DDX5 depletion and rescue with DDX5-R431Q. Cells were 
sequentially transfected with siDDX5A and then a second round of siRNA 
together with the replication competent HIV-1 proviral clone pLAI, with 
or without increasing concentrations of siDDX5A resistant DDX5-R431Q 
expressor construct. Supernatant was harvested 48 h post co-transfection 
and used to infect CD4 + TZM-bl indicator cells for assessing viral infectiv-
ity. TZM-bl cell lysates were harvested 48 h post infection and luciferase 
activity quantified. Each graph is a representative of at least two inde-
pendent experiments done in triplicate. Bars represent mean of triplicate 
samples ± SEM. (D) Western blot showing expression of DDX5 following 
knockdown and rescue with DDX5-S279L. (E) Western blot showing DDX5 
expression following knockdown and rescue with DDX5-R431Q. Statistical 
significance *P < 0.05, **P < 0.01.
Additional file 6: Table S1. List of siRNAs.
Additional file 7: Table S2. List of PCR and RT-qPCR.
Additional file 8: Table S3. RT-qPCR thermocycling conditions.
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